Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO‐B.O.S.S.)

Rare primary malignant bone sarcomas (RPMBS) account for 5%–10% of primary high‐grade bone tumors and represent a major treatment challenge. The outcome of patients with RPMBS enrolled in the EUROpean Bone Over 40 Sarcoma Study (EURO‐B.O.S.S) is presented.

[1]  A. Sinha,et al.  Primary Osseous Leiomyosarcoma with Vertebral and Nodal Metastasis in a Young Woman: A Rare Case Report , 2022, International journal of surgical pathology.

[2]  F. Bertucci,et al.  Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. , 2022, The Lancet. Oncology.

[3]  J. D. Thompson,et al.  Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival , 2021, Nature communications.

[4]  K. S. Hall,et al.  Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. , 2021, European journal of cancer.

[5]  David M. Thomas,et al.  Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities , 2021, Cancer.

[6]  E. Staals,et al.  Rare Primary Malignant Bone Sarcomas , 2020, Cancers.

[7]  M. Zucchetti,et al.  Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group , 2020, Cancer.

[8]  S. Ferrari,et al.  Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS) , 2020, Scientific Reports.

[9]  J. Blay,et al.  Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Blay,et al.  Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group , 2020, Cancer.

[11]  P. Casali,et al.  Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU) , 2020, ESMO Open.

[12]  J. Blay,et al.  Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses , 2019, BMC Cancer.

[13]  K. S. Hall,et al.  Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas – A nationwide population-based study , 2018, Journal of bone oncology.

[14]  H. Yasunaga,et al.  Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi‐institutional study , 2015, Cancer.

[15]  R. Maki.  Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. , 2007, The oncologist.

[16]  A. Bleyer,et al.  Malignant melanoma in the first three decades of life: A report from the U.S. Surveillance, Epidemiology and End Results (SEER) Program , 2004 .

[17]  M. van Glabbeke,et al.  Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Malcolm.  Bone tumours , 1991 .

[19]  S. Bielack,et al.  EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma , 2018, Tumori.

[20]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .